Decline Heir Digital Sign with airSlate SignNow

Decline heir digital sign

thanks so much so as everyone i think realizes at this time the real truth about health is that it's out of date uh and this old idea of prescriptive bad medicine which is what i was taught in medical school back in the 70s is no longer applicable and no longer helpful for these very complex illnesses and as we were just hearing uh things like things like mercury huge issue and we really need to look at these and look at organism organismal health so let me share some slides here and go through a couple of things and talk a little bit about what we've been doing with our latest trial and let me share that okay and let's pull this up here we go there we go okay so the whole idea of network medicine is that we need to quit thinking about human beings as being simple come in for seven minutes and you get a prescription that has absolutely nothing to do with what's causing the problem a hundred years ago of course most people were dying from simple illnesses things like pneumococcal pneumonia and on the other hand today virtually all of us are dying from complex chronic illnesses and i see there are about almost 200 people here so that means about 30 of us here today will die of alzheimer's disease and the challenge today is let's see if we can make that zero let me show you how this disease works let's look under the hood we spent 30 years published over 220 peer-reviewed papers on understanding what actually drives cognitive decline in alzheimer's disease so that we could fashion the first effective treatments and we've had unprecedented success in preventing and reversing cognitive decline and as you might imagine the sooner you start the better off the easier it is and the more complete uh return that you get okay so let's there we go all right so i want to just mention before we get started here the semantics of success because a lot of us have heard about a successful drug and there's been a lot of uh there's been a lot of argument a lot of controversy and as you may have heard when the fda approved this drug right here which is called adequamab which was back in june three of the expert panel members of their 11 expert panel members all of them were not enthusiastic in fact all of them said do not approve this the fda decided to approve it anyway and we could understand to some extent they were saying well hey we haven't had anything in many years maybe this is something the problem as you can see here is that the very best this drug did was not to make people better it was not to stabilize cognitive decline but in fact it was in one trial at one dose only to slow the decline here by 22 so...